Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

142.61 USD -11.32 (-7.35%)
Streaming Delayed Price Updated: 1:12 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Exact Sciences Cor

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing 
From PR Newswire
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group 
From PR Newswire
Should you invest in Exxon Mobil, Wells Fargo, General Motors, Etsy, or EXACT Sciences?
InvestorsObserver issues critical PriceWatch Alerts for XOM, WFC, GM, ETSY, and EXAS. 
From PR Newswire
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
- Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M 
From PR Newswire
Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). 
From PR Newswire
Exact Sciences to participate in J.P. Morgan Healthcare Conference
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. 
From PR Newswire
Cognitive Assessment & Training in Healthcare Market Could Reach $45 Billion by 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cognitive Assessment & Training in Healthcare Market Could Reach $45 Billion by 2026
Financialnewsmedia.com News Commentary 
From PR Newswire
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with... 
From PR Newswire
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully defined the benefit of chemotherapy in... 
From PR Newswire
Exact Sciences to participate in December investor conference
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. 
From PR Newswire
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes. 
From PR Newswire
Exact Sciences to participate in November investor conferences
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate by webcast. 
From PR Newswire
Thinking about buying stock in Apple, Titan Pharmaceuticals, Tupperware Brands, EXACT Sciences, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, TTNP, TUP, EXAS, and ROKU. 
From PR Newswire
Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
Cologuard® remains a recommended screening method in the draft 
From PR Newswire
Thinking about buying stock in Xilinx, General Electric, EXACT Sciences, Harley-Davidson, or American International?
InvestorsObserver issues critical PriceWatch Alerts for XLNX, GE, EXAS, HOG, and AIG. 
From PR Newswire
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its common stock, par value $0.01 per share, in a... 
From PR Newswire
Exact Sciences Announces Third Quarter 2020 Results
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period... 
From PR Newswire
Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives 
From PR Newswire
Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer
Comprehensive genomic profiling panel aids therapy selection decisions for a breadth of solid tumor types 
From PR Newswire
Exact Sciences schedules third quarter 2020 earnings call
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020.... 
From PR Newswire
Thinking about trading options or stock in Netflix, EXACT Sciences, Apple, American Airlines, or Purple Innovation?
InvestorsObserver issues critical PriceWatch Alerts for NFLX, EXAS, AAPL, AAL, and PRPL. 
From PR Newswire
Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
Successful collaboration will continue to support Cologuard adoption through 2022 
From PR Newswire
Researchers Look for New Ways to Boost Diagnostic Capabilities
FinancialBuzz.com News Commentary 
From PR Newswire
Thinking about trading options or stock in Royal Caribbean Cruises, Caesars Entertainment, EXACT Sciences, Boeing, or AT&T?
InvestorsObserver issues critical PriceWatch Alerts for RCL, CZR, EXAS, BA, and T. 
From PR Newswire
Exact Sciences to participate in Cowen Liquid Biopsy Summit
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following event and invited investors to participate by webcast. 
From PR Newswire
Bullish Beta Stocks Showing Potential Of High Returns: $MPLX $EXAS $LEN
Tags The Market Signal
From The Market Signal
Diagnostic Methods Benefit from Rapidly Advancing Technologies
FinancialBuzz.com News Commentary 
From PR Newswire
Exact Sciences to participate in September investor conference
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. 
From PR Newswire
Novel Cancer Treatments Arise as Scientists Search for Answers
FinancialBuzz.com News Commentary 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X